Loading…
Arrowhead Pharmaceuticals, Inc. is projected to rise to $108.91 by 2027, a +43% move from its current price of $76.40. ARWR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $74.32 | $76.51 | $78.76 | +0.14% |
| Jul 13 | $73.54 | $76.61 | $79.82 | +0.28% |
| Jul 14 | $72.96 | $76.72 | $80.67 | +0.42% |
| Jul 15 | $72.50 | $76.83 | $81.41 | +0.56% |
| Jul 16 | $72.11 | $76.93 | $82.08 | +0.70% |
| Jul 17 | $71.76 | $77.04 | $82.71 | +0.84% |
| Jul 18 | $71.45 | $77.15 | $83.29 | +0.98% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $71.45 | $77.15 | $83.29 | +0.98% |
| Week 2 | $69.90 | $77.90 | $86.82 | +1.97% |
| Week 3 | $68.88 | $78.66 | $89.84 | +2.96% |
| Week 4 | $68.14 | $79.43 | $92.60 | +3.97% |
| Week 5 | $67.57 | $80.21 | $95.21 | +4.99% |
| Week 6 | $67.13 | $80.99 | $97.73 | +6.01% |
| Week 7 | $66.77 | $81.79 | $100.18 | +7.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. (ARWR) trades at $76.40 and has a market cap of $10.76B, ranking 883 by market capitalization. The stock sits in the Healthcare sector as a biotech developer with a pipeline focused on RNAi-based therapies.
The price outlook implies long-run upside, with the 2026 forecast showing an average price of $76.40 and a broad range ($55.01 to $117.56). The longer-horizon forecast points to bullish momentum, with 2030 and beyond delivering higher averages (2030 avg $159.61; 2040 avg $573.68; 2050 avg $1,132.02) and sizable ROIs (2030 ROI 108.9; 2040 ROI 650.9; 2050 ROI 1381.7).
Across the forecast, the max values rise with time (2030 max $235.02; 2040 max $987.85; 2050 max $2,140.28), underscoring a potential multi-year upside while acknowledging the inherent uncertainty of projections.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 13.8% above — a clean break opens room to run.
A major ceiling 23.4% above — clearing it would confirm fresh momentum.
Key ARWR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARWR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $83.93 | Sell | $81.87 | Sell |
| MA 10 | $82.50 | Sell | $82.04 | Sell |
| MA 20 | $80.57 | Sell | $80.70 | Sell |
| MA 50 | $77.53 | Sell | $77.05 | Sell |
| MA 100 | $70.37 | Buy | $71.72 | Buy |
| MA 200 | $61.80 | Buy | $61.68 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.59 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -97.74 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -4.38 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.38 | Buy |
| Awesome (5,34) | 5.66 | Buy |
| Ultimate (7,14,28) | 38.55 | Neutral |
| Momentum (10) | -2.87 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 83.58 | Sell |
| ADX (14) | 18.42 | Neutral |
| ATR (14) | 2.03 | Info |
In the last 30 days, Arrowhead traded within a range of $63.11 to $92.48.
The technical picture is labeled bullish, with RSI14 at 40. The 50-day simple moving average is $77.53, above the 200-day simple moving average of $61.80. Support is cited at $70.73 and resistance at $86.97, framing a near-term trading band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $55.01 | $76.40 | $117.56 | 0% | Neutral | |
| $86.20 | $108.91 | $145.87 | +43% | Bullish | |
| $99.73 | $129.81 | $180.75 | +70% | Bullish | |
| $111.33 | $148.53 | $213.20 | +94% | Bullish | |
| $117.04 | $159.61 | $235.02 | +109% | Bullish | |
| $132.49 | $184.31 | $277.50 | +141% | Bullish | |
| $165.30 | $234.29 | $359.84 | +207% | Bullish | |
| $201.81 | $291.08 | $455.20 | +281% | Bullish | |
| $213.00 | $312.37 | $496.67 | +309% | Bullish | |
| $218.41 | $325.45 | $525.47 | +326% | Bullish | |
| $358.06 | $573.68 | $987.85 | +651% | Bullish | |
| $622.98 | $1,132.02 | $2,140.28 | +13.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $55.01 | $76.40 | $92.42 | +0.00% |
| August 2026 | $69.36 | $82.01 | $99.69 | +7.35% |
| September 2026 | $72.80 | $86.73 | $106.66 | +5.75% |
| October 2026 | $73.12 | $87.66 | $108.88 | +1.07% |
| November 2026 | $73.81 | $88.97 | $111.41 | +1.49% |
| December 2026 | $76.90 | $93.16 | $117.56 | +4.72% |
Click any year to see its month-by-month ARWR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ARWR price prediction for 2026 points to an average of $76.40 (low $55.01, high $117.56) — a potential gain of 0% on today's $76.40. A consolidation phase looks the most probable path here.
In 2027, ARWR is projected to trade between $86.20 and $145.87, averaging $108.91 — a potential gain of +43% from today's $76.40. That is up +43% on the projected 2026 average. Momentum favours further upside here.
Arrowhead Pharmaceuticals, Inc.'s 2028 outlook centres on $129.81, within a $99.73 to $180.75 range. That is up +19% on the projected 2027 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ARWR could reach as high as $213.20, with a base case around $148.53 and support toward $111.33 — roughly +94% from $76.40. Momentum favours further upside here.
Expect ARWR to range from $117.04 to $235.02 through 2030. The $159.61 average target implies a +109% move from current prices. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ARWR price prediction for 2031 points to an average of $184.31 (low $132.49, high $277.50) — a potential gain of +141% on today's $76.40. Momentum favours further upside here.
In 2032, ARWR is projected to trade between $165.30 and $359.84, averaging $234.29 — a potential gain of +207% from today's $76.40. That is up +27% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Arrowhead Pharmaceuticals, Inc.'s 2033 outlook centres on $291.08, within a $201.81 to $455.20 range. That is up +24% on the projected 2032 average. That marks a +281% change versus current levels. Momentum favours further upside here.
By 2034, ARWR could reach as high as $496.67, with a base case around $312.37 and support toward $213.00 — roughly +309% from $76.40. Buyers look set to stay in control over this stretch.
Expect ARWR to range from $218.41 to $525.47 through 2035. The $325.45 average target implies a +326% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The ARWR price prediction for 2040 points to an average of $573.68 (low $358.06, high $987.85) — a potential gain of +651% on today's $76.40. Buyers look set to stay in control over this stretch.
In 2050, ARWR is projected to trade between $622.98 and $2,140.28, averaging $1,132.02 — a potential gain of +13.8x from today's $76.40. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ARWR today (≈ 13.089005 ARWR) could be worth
$14,816.97
+$13,816.97 (+1382%) by 2050 · US Dollar
Based on the average projected ARWR price of $1,132.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARWRwould be worth at today's price.
$1,000 invested in ARWR on Jul 10, 2025 (≈ 53.022268 ARWR) would be worth
$4,050.9
+$3,050.9 (+305.1%) today · 4.05× · US Dollar
Based on a ARWR entry price of $18.86 vs. today's $76.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $83.99 | $909.63 | -9.0% |
| 1 month ago | $70.73 | $1,080.16 | +8.0% |
| 3 months ago | $65.14 | $1,172.86 | +17.3% |
| 6 months ago | $65.93 | $1,158.8 | +15.9% |
| 1 year ago | $18.86 | $4,050.9 | +305.1% |
| All time (5.0y) ago | $65.78 | $1,161.45 | +16.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARWR forecast.
Our base-case forecast reaches $150.00 around 2030.
Implied market cap at $150.00: $21.13B
The multi-year forecast shows a clear, bullish progression after 2026. The avg price climbs from $76.40 in 2026 to $159.61 in 2030, then to $573.68 in 2040 and $1,132.02 in 2050, signaling substantial upside potential over the coming decades. The associated ROI grows from 0 in 2026 to 108.9 in 2030, 650.9 in 2040, and 1,381.7 in 2050, highlighting the long-term upside embedded in the model’s path.
Key year markers include 2030 with avg $159.61 and max $235.02 (min $117.04), 2040 with avg $573.68 and max $987.85 (min $358.06), and 2050 with avg $1,132.02 and max $2,140.28 (min $622.98). The sentiment remains bullish across 2027 through 2050, reflecting a sustained, though uncertain, upward trajectory.
These are estimates for planning purposes and are not guarantees. Real-world outcomes depend on market conditions, development progress, regulatory developments, and other factors outside the dataset's scope.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $159.61, with a min of $117.04 and a max of $235.02; the predicted ROI is 108.9 and sentiment is BULLISH.
The forecast indicates neutral sentiment in 2026, followed by BULLISH sentiment from 2027 onward, with rising avg prices and ROI up to 1,381.7 by 2050. These are estimates, not guarantees.
Yes. The 2030 forecast lists a max of $235.02, with an avg of $159.61 and ROI 108.9, indicating that reaching or approaching that level is within the forecast scenario.
Current price is $76.40 and market cap is $10.76B, with a rank of 883.
For 2050, the forecast shows min $622.98, avg $1,132.02, max $2,140.28, ROI 1381.7, and sentiment BULLISH.
Arrowhead Pharmaceuticals, Inc. Community Discussion
0Share your Arrowhead Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.